Head to Head Review: Intellia Therapeutics (NASDAQ:NTLA) versus Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) and Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares Ionis Pharmaceuticals and Intellia Therapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ionis Pharmaceuticals $960.09 million 4.86 -$381.39 million ($3.32) -8.44
Intellia Therapeutics $67.67 million 20.38 -$412.69 million ($3.35) -2.93

Ionis Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Ionis Pharmaceuticals and Intellia Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals 1 3 19 0 2.78
Intellia Therapeutics 4 7 9 1 2.33

Ionis Pharmaceuticals currently has a consensus target price of $75.71, suggesting a potential upside of 170.27%. Intellia Therapeutics has a consensus target price of $21.44, suggesting a potential upside of 118.24%. Given Ionis Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Intellia Therapeutics.

Profitability

This table compares Ionis Pharmaceuticals and Intellia Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals -56.98% -120.62% -16.99%
Intellia Therapeutics -805.75% -64.74% -50.72%

Risk and Volatility

Ionis Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.

Summary

Ionis Pharmaceuticals beats Intellia Therapeutics on 9 of the 15 factors compared between the two stocks.

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

About Intellia Therapeutics

(Get Free Report)

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.